This recombinant monoclonal antibody is developed as a research-grade biosimilar to DR-01, targeting KLRD1 (Killer cell Lectin-like Receptor subfamily D member 1), also known as CD94. KLRD1 is a C-type lectin receptor expressed predominantly on natural killer (NK) cells and a subset of CD8+ T cells, where it forms heterodimers with NKG2 family members to regulate cytotoxic lymphocyte activity. By interacting with HLA-E molecules on target cells, KLRD1/CD94 complexes function as critical immune checkpoints that modulate NK cell-mediated cytotoxicity and immune surveillance. Dysregulation of KLRD1 expression has been implicated in various immunological disorders, viral infections, and cancer immune evasion mechanisms, making it a valuable target for immunological research.
The reference antibody DR-01 has been utilized in studies examining NK cell biology, immune checkpoint regulation, and tumor immunology. This biosimilar provides researchers with a reliable tool for investigating KLRD1-mediated immune responses, NK cell phenotyping, and the role of innate immunity in disease pathogenesis. It supports diverse experimental approaches in immunology, oncology, and infectious disease research.
Email: support@cusabio.com
Distributors Worldwide